Analyst picks & changes

AutoImmune Inc.

(AIMM)

Business: Autoimmune

Dillon, Read analyst Michael King began coverage of the Lexington, Mass., company with a "buy." Positive data on a Phase II trial of

Read the full 289 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE